630 related articles for article (PubMed ID: 27381025)
1. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
2. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
3. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
4. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
5. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
6. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
[TBL] [Abstract][Full Text] [Related]
7. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
Rizk E; Wilson AD; Murillo MU; Putney DR
Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
10. Concordance between Activated Partial Thromboplastin Time and Antifactor Xa Assay for Monitoring Unfractionated Heparin in Hospitalized Hyperbilirubinemic Patients.
Mahmoud L; Zullo AR; McKaig D; Berard-Collins CM
R I Med J (2013); 2016 Mar; 99(3):33-7. PubMed ID: 26929970
[TBL] [Abstract][Full Text] [Related]
11. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
Frugé KS; Lee YR
Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
[TBL] [Abstract][Full Text] [Related]
12. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
13. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
14. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
15. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
16. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
17. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
18. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
19. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
20. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]